Imidazoline receptors in the heart: A novel target and a novel mechanism of action that involves atrial natriuretic peptides

Brazilian Journal of Medical and Biological Research

Volumn 37, Issue 8, 2004, Pages 1239-1245

  Mukaddam Daher, Suhayla ^a   Gutkowska, J ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Atrial natriuretic peptide; Brain natriuretic peptide; Heart; Hypertension; Imidazoline receptors; Moxonidine; Sympathetic nerve activity

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CLONIDINE; IMIDAZOLINE I1 RECEPTOR; INTERLEUKIN 1BETA; MOXONIDINE; RILMENIDINE;

ADRENERGIC STIMULATION; ARTICLE; BLOOD PRESSURE REGULATION; BRAIN STEM; DIURESIS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; HAMSTER; HEART ATRIUM RECEPTOR; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERTENSION; IN VIVO STUDY; LONG TERM EXPOSURE; MEDULLA OBLONGATA; NATRIURESIS; NONHUMAN; PEPTIDE SYNTHESIS; PROTEIN BLOOD LEVEL; RECEPTOR UPREGULATION; SPONTANEOUSLY HYPERTENSIVE RAT;

CRICETINAE;

EID: 4444304337     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2004000800015     Document Type: Article

References (35)

1. Esler M (2000). The sympathetic system and hypertension. American Journal of Hypertension, 13: 99S-105S.
2. Bricca G, Dontenwill M, Molines A, Feldman J, Belcourt A & Bousquet P (1989). The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem. European Journal of Pharmacology, 162: 1-9.
3. Bousquet P, Feldman J, Bloch R & Schwartz J (1981) The nucleus reticularis lateralis: a region highly sensitive to clonidine. European Journal of Pharmacology, 69: 389-392.
4. Bousquet P, Feldman J & Schwartz J (1984). Central cardiovascular effects of α-adrenergic drugs: difference between catecholamines and imidazolines. Journal of Pharmacology and Experimental Therapeutics, 230: 232-236.
5. Meeley MP, Ernsberger PR, Granata AR & Reis DJ (1986). An endogenous clonidine-displacing substance from bovine brain: receptor binding and hypotensive actions in the ventrolateral medulla. Life Sciences, 38: 1119-1126.
6. 1-imidazoline receptors in the rostral ventrolateral medulla. Journal of Cardiovascular Pharmacology, 24: S1-S8.
7. Michel MC & Insel PA (1989). Are there multiple imidazoline binding sites? Trends in Pharmacological Sciences, 10: 342-344.
8. Raddatz R, Parini A & Lanier SM (1997). Localization of the imidazoline binding domain on monoamine oxidase B. Molecular Pharmacology, 52: 549-553.
9. 1-imidazoline receptor and its cellular signaling pathways. Annals of the New York Academy of Sciences, 881: 35-53.
10. 1-imidazoline receptors in rat brainstem. Life Sciences, 61: 1973-1983.
11. Hamilton CA, Jardine E & Reid JL (1993). Down-regulation of imidazoline sites in rabbit kidney. European Journal of Pharmacology, 243: 95-97.
12. Li G, Regunathan S, Barrow C, Eshraghi J, Cooper R & Reis DJ (1994). Agmatine: an endogenous clonidine displacing substance in the brain. Science, 263: 966-969.
13. Edwards L, Fishman D, Horowitz P, Bourbon N, Kester M & Ernsberger P (2001). The I1-imidazoline receptor in PC12 pheochromocytoma cells activates protein kinases C, extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK). Journal of Neurochemistry, 79: 931-940.
14. 1-imidazoline receptors to the cAMP pathway: studies with a highly selective ligand, benazoline. Molecular Pharmacology, 57: 1142-1151.
15. El-Ayoubi R, Gutkowska J, Regunathan S & Mukaddam-Daher S (2002). Imidazoline receptors in the heart: characterization, distribution, and regulation. Journal of Cardiovascular Pharmacology, 39: 875-883.
16. El-Ayoubi R, Menaouar A, Gutkowska J & Mukaddam-Daher S (2004). Imidazoline receptors but not alpha2 adrenoceptors are regulated in SHR heart by chronic moxonidine treatment. Journal of Pharmacology and Experimental Therapeutics (in press).
17. 1 imidazoline preferring receptors: two unique sites mediating natriuresis in the rat. Cardiovascular Drugs and Therapeutics, 8 (Suppl 1): 43-48.
18. Smyth DD, Pirnat D, Forzley B & Penner SB (2003). Apparent absence of direct renal effect of imidazoline receptor agonists. Annals of the New York Academy of Sciences, 1009: 288-295.
19. Regunathan S, Feinstein DL & Reis DJ (1999) Antiproliferative and anti-inflammatory actions of imidazoline agents. Are imidazoline receptors involved? Annals of the New York Academy of Sciences, 881: 410-419.
20. Mall G, Greber D, Gharenhbaghi H, Wiest G, Amann K & Mattfeldt T (1991). Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats (SHR)-stereological studies on myocytes, capillaries, arteries, and cardiac interstitium. Basic Research in Cardiology, 86 (Suppl 3): 33-44.
21. Thomas L, Gasser B, Bousquet P & Monassier L (2003). Hemodynamic and cardiac anti-hypertrophic actions of clonidine in Goldblatt one-kidney, one-clip rats. Journal of Cardiovascular Pharmacology, 41: 203-209.
22. Sadowski Z, Szwed H, Kuch-Wocial A et al. (1998). Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled (versus nifedipine) study. Journal of Hypertension, 16: S55-S62.
23. Roegel JC, Yannoulis N, De Jong W, Feldman J & Bousquet P (1998). Preventive effect of rilmenidine on the occurrence of neurogenic ventricular arrhythmias in rabbits. Journal of Hypertension, 16: S39-S43.
24. Szelenyi J, Kiss JP & Vizi ES (2000). Differential involvement of sympathetic nervous system and immune system in the modulation of TNF-alpha production by alpha2- and beta-adrenoceptors in mice. Journal of Neuroimmunology, 103: 34-40.
25. Zaitsev SV, Appelskog IB, Kapelioukh IL, Yang SN, Kohler M, Efendic S & Berggren PO (2001). Imidazoline compounds protect against interleukin 1beta-induced beta-cell apoptosis. Diabetes, 50: S70-S76.
26. Steinhelper ME, Cochrane KL & Field LJ (1990). Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension, 16: 301-307.
27. Melo LG, Veress AT, Ackermann U, Steinhelper ME, Pang SC, Tse Y & Sonnenberg H (1999). Chronic regulation of arterial blood pressure in ANP transgenic and knockout mice: role of cardiovascular sympathetic tone. Cardiovascular Research, 43: 437-444.
28. Oliver PM, Fox JE, Kim R, Rockman HA, Kim HS, Reddick RL, Pandey KN, Milgram SL, Smithies O & Maeda N (1997). Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proceedings of the National Academy of Sciences, USA, 94: 14730-14735.
29. Knowles JW, Esposito G, Mao L, Hagaman JR, Fox JE, Smithies O, Rockman HA & Maeda N (2001). Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. Journal of Clinical Investigation, 107: 975-984.
30. Tamura N, Ogawa Y, Chusho H et al. (2000). Cardiac fibrosis in mice lacking brain natriuretic peptide. Proceedings of the National Academy of Sciences, USA, 97: 4239-4244.
31. Chatterjee PK, Hawksworth GM & McLay JS (1999). Cytokine-stimulated nitric oxide production in the human renal proximal tubule and its modulation by natriuretic peptides: A novel immunomodulatory mechanism? Experimental Nephrology, 7: 438-448.
32. Mukaddam-Daher S & Gutkowska J (2000). Atrial natriuretic peptide is involved in renal actions of moxonidine. Hypertension, 35: 1215-1220.
33. Mukaddam-Daher S & Gutkowska J (1999). The renal actions of moxonidine are mediated by atrial natriuretic peptide and involve the opioid receptors. Annals of the New York Academy of Sciences, 881: 385-387.
34. Menaour A, El-Ayoubi R, Jankowski M, Gutkowska J & Mukaddam-Daher S (2002). Chronic imidazoline receptor activation in spontaneously hypertensive rats. American Journal of Hypertension, 15: 803-808.
35. 1-receptors and natriuretic peptides by chronic treatment with moxonidine in spontaneously hypertensive rats. Annals of the New York Academy of Sciences, 1009: 274-278.